Newsroom

March 10, 2016 – Clinical validation data from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study were published online in the American Journal of Obstetrics & Gynecology. The article presents the performance in a rigorous clinical validation of Sera’s PreTRM® test for objectively and accurately predicting the risk of spontaneous preterm birth (sPTB) in asymptomatic pregnant women as early as 19 weeks of pregnancy.

February 4, 2016 – Sera, Inc., a women’s healthcare company, today announced that results from the 5,501-patient Proteomic Assessment of Preterm Risk (PAPR) study validate the newly available PreTRM® test, which accurately and objectively predicts spontaneous preterm birth (sPTB), in pregnant women whose blood is drawn for analysis as early as 19 weeks of pregnancy. The data were presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting in Atlanta, Georgia.

January 7, 2016 — Sera, Inc., a women’s healthcare company, today announced that findings from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study will be reported in an oral presentation during the Society for Maternal-Fetal Medicine’s (SMFM) 36th Annual Pregnancy Meeting™ in Atlanta, February 1-6, 2016.

December 21, 2015–Sera, Inc. today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference.

November 24, 2015 – Sera, Inc., today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference . Dr. Critchfield’s presentation will take place at 10:30 AM ET on Wednesday, December 2, 2015 at the Lotte New York Palace Hotel in New York, NY.

October 19, 2015 – Sera, Inc., today announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth.

Dec 23, 2014 – Sera announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the 33rd annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015.

Jan 7, 2015 – Sera announced that it has closed $20 Million in Series B financing, led by Chione, Ltd, a European investment company, and appointed Mansoor Raza Mirza, M.D. to its Board of Directors.

Feb 24, 2015–Sera announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its Board of Directors. Dr. Oronsky’s addition to the Sera board occurs as the company is in the final stages of developing PreTRM™, its novel proteomic predictor for preterm birth risk, prior to its commercial launch. In addition, Douglas Fisher, M.D., joins the company’s management team as Chief Business Officer.

Feb 4, 2015-Sera announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. The additional funding will help Sera expand the reach of its proteomic technology, to develop new tests designed to predict the risk of preterm birth for women in developing countries around the world.